IRA Reality Check: Four Strategies for Adapting Hub and Copay Programs

In Bracing for Impact: The Future of Hub, PAP, and Affordability Programs Under the Inflation Reduction Act, I described how the Inflation Reduction Act of 2022 (IRA) introduced prescription drug pricing reforms that pose significant financial challenges for drug makers and change the landscape for hub and copay support programs.

Since then, there have been numerous developments surrounding the IRA, from lawsuit updates to price negotiations, and pressure on hub and copay programs continues to mount. Let’s examine some of the latest trends and see how they could impact hub and affordability programming.